ABP 692 vs Ofatumumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: CD20 · full Multiple Sclerosis pipeline
ABP 692
Developed by Amgen
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT06700343 (registry estimate)
No aligned efficacy figure on record for this race.
Ofatumumab
Marketed by Novartis and partners
NCT02792231 · Phase 3 · completed
This was a large, randomized, quadruple-blind, active-controlled trial of 955 participants, comparing ofatumumab with teriflunomide. The prespecified primary clinical endpoint, annualized confirmed relapse rate, was significantly better with ofatumumab (p<0.001), supporting a strong evidence grade despite mixed findings for some secondary measures.
Next expected readout: April 2027 · NCT05090371 (registry estimate)
Reported efficacy
Annualized Relapse Rate (ARR) (Baseline up to 2.5 years): Annualized Relapse Rate (ASCLEPIOS II): 0.10 (ofatumumab) vs 0.25 (teriflunomide); difference -0.15 (95% CI: -0.20, -0.09) (met)
Result source: NCT02792231
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ABP 692 | Ofatumumab |
|---|---|---|
| Annualised relapse rate | —Trial running · NCT06700343 | 0.1 vs 0.3vs TERNCT027922314 other results
|
| Free of 3-month confirmed disability progression (%) | —Trial running · NCT06700343 | —Not posted · NCT04788615 |
| New or enlarging T2 lesions | —Trial running · NCT06700343 | —Not posted · NCT04788615 |
Annualised relapse rate
- ABP 692
- —Trial running · NCT06700343
- Ofatumumab
- 0.1 vs 0.3vs TERNCT02792231
4 other results
- 0.1 vs 0.2 NCT02792218
- 0.1 vs 0.2 NCT02792231
- 0.1 vs 0.2 NCT02792218
- 0.3 vs 0.6 NCT03249714
Free of 3-month confirmed disability progression (%)
- ABP 692
- —Trial running · NCT06700343
- Ofatumumab
- —Not posted · NCT04788615
New or enlarging T2 lesions
- ABP 692
- —Trial running · NCT06700343
- Ofatumumab
- —Not posted · NCT04788615
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ABP 692: no structured comparison results are available for Multiple Sclerosis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ABP 692: 0 of 4 rows · Ofatumumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ofatumumab |
|---|---|
| Dropout rate | 17%20 mga NCT02792231 · Phase 3 show 26 more results—20mg NCT02792231 · Phase 3 10.5%20 mg NCT02792218 · Phase 3 —20 mg NCT02792218 · Phase 3 19.8%20 mg NCT04486716 · Phase 3 2.9%60 mg q12w NCT01457924 · Phase 2 9.4%60 mg q4w NCT01457924 · Phase 2 6.3%30 mg q12w NCT01457924 · Phase 2 14.7%3 mg q12w NCT01457924 · Phase 2 0%700 mg NCT00640328 · Phase 2 · monotherapy 9.1%300 mg NCT00640328 · Phase 2 · monotherapy 0%100 mg NCT00640328 · Phase 2 · monotherapy 7.6%Ofatumumab NCT05084638 · Phase 4 · registry result, not featured evidence —Ofatumumab-Treated NCT05084638 · Phase 4 · registry result, not featured evidence 4% NCT05199571 · Phase 4 · registry result, not featured evidence —20 mg NCT04353492 · Phase 3 · registry result, not featured evidence 6.9%Ofatumumab NCT04353492 · Phase 3 · registry result, not featured evidence 7%20 mg NCT03249714 · Phase 2 · registry result, not featured evidence —20 mg NCT03249714 · Phase 2 · registry result, not featured evidence —20 mg NCT03249714 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0.8%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.1%20 mga NCT02792231 · Phase 3 show 26 more results—20mg NCT02792231 · Phase 3 3.2%20 mg NCT02792218 · Phase 3 —20 mg NCT02792218 · Phase 3 4.5%20 mg NCT04486716 · Phase 3 0%60 mg q12w NCT01457924 · Phase 2 3.1%60 mg q4w NCT01457924 · Phase 2 3.1%30 mg q12w NCT01457924 · Phase 2 11.8%3 mg q12w NCT01457924 · Phase 2 0%700 mg NCT00640328 · Phase 2 · monotherapy 9.1%300 mg NCT00640328 · Phase 2 · monotherapy 0%100 mg NCT00640328 · Phase 2 · monotherapy —Ofatumumab NCT05084638 · Phase 4 · registry result, not featured evidence —Ofatumumab-Treated NCT05084638 · Phase 4 · registry result, not featured evidence — NCT05199571 · Phase 4 · registry result, not featured evidence —20 mg NCT04353492 · Phase 3 · registry result, not featured evidence 0.5%Ofatumumab NCT04353492 · Phase 3 · registry result, not featured evidence —20 mg NCT03249714 · Phase 2 · registry result, not featured evidence —20 mg NCT03249714 · Phase 2 · registry result, not featured evidence —20 mg NCT03249714 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0.8%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —20 mga NCT02792231 · Phase 3 show 26 more results8.7%20mg NCT02792231 · Phase 3 —20 mg NCT02792218 · Phase 3 11%20 mg NCT02792218 · Phase 3 5.9%20 mg NCT04486716 · Phase 3 2.9%60 mg q12w NCT01457924 · Phase 2 6.3%60 mg q4w NCT01457924 · Phase 2 0%30 mg q12w NCT01457924 · Phase 2 2.9%3 mg q12w NCT01457924 · Phase 2 0%700 mg NCT00640328 · Phase 2 · monotherapy 18.2%300 mg NCT00640328 · Phase 2 · monotherapy 0%100 mg NCT00640328 · Phase 2 · monotherapy —Ofatumumab NCT05084638 · Phase 4 · registry result, not featured evidence 6.7%Ofatumumab-Treated NCT05084638 · Phase 4 · registry result, not featured evidence 0% NCT05199571 · Phase 4 · registry result, not featured evidence 6%20 mg NCT04353492 · Phase 3 · registry result, not featured evidence —Ofatumumab NCT04353492 · Phase 3 · registry result, not featured evidence —20 mg NCT03249714 · Phase 2 · registry result, not featured evidence 2.5%20 mg NCT03249714 · Phase 2 · registry result, not featured evidence 2.3%20 mg NCT03249714 · Phase 2 · registry result, not featured evidence 1.6%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 3.1%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 20mga injection related reaction 24.7% injection related reaction 24.7% nasopharyngitis 18.3% NCT02792231 · Phase 3 show 18 more results3 mg q12w injection related reaction 47.1% urinary tract infection 8.8% anaemia 5.9% NCT01457924 · Phase 2 700 mg rash 57.1% (placebo 50%) throat irritation 28.6% (placebo 0%) upper respiratory tract infection 28.6% (placebo 75%) NCT00640328 · Phase 2 · monotherapy 300 mg throat irritation 36.4% (placebo 0%) rash 27.3% (placebo 50%) viral infection 27.3% (placebo 0%) NCT00640328 · Phase 2 · monotherapy 100 mg nasopharyngitis 50% (placebo 25%) throat irritation 37.5% (placebo 0%) depression 25% (placebo 0%) NCT00640328 · Phase 2 · monotherapy chills 36.1% headache 27.7% myalgia 26.1% NCT05084638 · Phase 4 · registry result, not featured evidence injection related reaction 43.4% covid-19 12.1% upper respiratory tract infection 12.1% NCT05199571 · Phase 4 · registry result, not featured evidence 20 mg injection related reaction 53.4% covid-19 37% nasopharyngitis 17.1% NCT04353492 · Phase 3 · registry result, not featured evidence 20 mg nasopharyngitis 17.5% (placebo 19%) rash 7.5% (placebo 0%) alanine aminotransferase increased 5% (placebo 4.8%) NCT03249714 · Phase 2 · registry result, not featured evidence 20 mg injection related reaction 20.9% (placebo 19%) nasopharyngitis 14% (placebo 19%) oral herpes 9.3% (placebo 0%) NCT03249714 · Phase 2 · registry result, not featured evidence 20 mg injection related reaction 32% headache 10.2% injection site reaction 8.6% NCT03560739 · Phase 2 · registry result, not featured evidence 20 mg injection related reaction 38.5% diarrhoea 7.7% fatigue 7.7% NCT03560739 · Phase 2 · registry result, not featured evidence 20 mg injection related reaction 46.2% asthenia 7.7% cough 7.7% NCT03560739 · Phase 2 · registry result, not featured evidence 20 mg injection related reaction 22.3% injection site reaction 13.1% headache 5.4% NCT03560739 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ofatumumab
show 4 more results
show 17 more results
show 5 more results
show 11 more results
show 1 more result
show 6 more results
show 1 more result
show 3 more results
show 3 more results
show 9 more results
+ 26 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABP 692's landscape · Ofatumumab's landscape